Conclusions
High neutralizing titer CCP therapy combined with FPV showed non-inferiority to sotrovimab in preventing hospitalization, emergency room visits, oxygen supplementation, and mortality in mild-to-moderate COVID-19 cases. This treatment approach may serve as an alternative to neutralizing monoclonal antibodies when dealing with emerging variants that have spike protein mutations.